Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention APC, the most common co-covered peer. Eric Andersen appears in 1 tracked Biotech story from August 14, 2026. The tracked stories average 2 original sources each.
Last mentioned: Aug 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention APC, the most common co-covered peer. Eric Andersen appears in 1 tracked Biotech story from August 14, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eric Andersen. Shared-story counts are live from our verified record — not editorial picks.
Maravai's Q2 2026 biotech results show adjusted EBITDA improved $19.1 million to $8.7 million, with discovery mRNA revenue up 17% and GMP consumables up 55%. The company raised full-year adjusted EBITDA guidance to $33-35 million.
Source: Motley Fool Transcribing (us) · fool.com
Eric Andersen is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
